GenBio AI has appointed Dr. Ziv Bar-Joseph as co-founder and chief scientific officer, aiming to strengthen its research efforts at the intersection of artificial intelligence and biology.
In this role, Bar-Joseph will lead the integration of GenBio AI’s multiscale foundation models, with a focus on their applications in drug discovery and medicine. His appointment comes as the company advances its work on AI-driven biological research.
Bar-Joseph previously held leadership positions at Sanofi, where he served as vice president and head of R&D data and computational sciences. He has worked on machine learning, computational biology, and data science initiatives aimed at accelerating drug and vaccine discovery. In addition, he is a professor of computer science at Carnegie Mellon University (CMU), specializing in biological systems modeling and AI applications in genomics and systems biology. He received the Overton Prize in computational biology in 2012.
“GenBio AI is building a world-class research environment to develop the first AI-driven Digital Organism (‘AIDO’), and I’m excited to be part of the team advancing AI-driven biology,” Bar-Joseph said.
Margarita Finance unveils AI-powered trading agent
GenBio AI co-founder and chief scientist Eric Xing described Bar-Joseph’s expertise as “instrumental” in shaping the company’s research and development. “Ziv is a highly accomplished colleague from CMU, and his expertise in computational biology and AI is unparalleled,” Xing said.
GenBio AI focuses on developing multiscale foundation models to analyze biological systems at different levels, from cells to organs. The company has published six technical papers detailing its work on AIDO at the Neural Information Processing Systems (NeurIPS) conference.
With operations in Palo Alto, Abu Dhabi, and Paris, GenBio AI is working on a platform designed to model complex biological systems across molecular, cellular, and phenotypic levels.
Featured image credit: GenBio
